Product Name:(R)-1-Amino-2-propanol

IUPAC Name:(2R)-1-aminopropan-2-ol

CAS:2799-16-8
Molecular Formula:C3H9NO
Purity:95%
Catalog Number:CM116508
Molecular Weight:75.11

Packing Unit Available Stock Price($) Quantity
CM116508-100g in stock ƓƓƓ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:2799-16-8
Molecular Formula:C3H9NO
Melting Point:-
Smiles Code:C[C@@H](O)CN
Density:
Catalog Number:CM116508
Molecular Weight:75.11
Boiling Point:
MDL No:MFCD00064428
Storage:

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

Alcohols
Alcohol is a type of organic compound that carries at least one hydroxyl ( −OH) functional group bound to a saturated carbon atom.
Repotrectinib
Repotrectinib receives approval for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) from the U.S. FDA on November 15, 2023. ROS1 gene is altered in about 1-2% of patients with NSCLC. ROS1-positive lung cancer tends to be aggressive and can spread to the brain and the bones.
Repotrectinib is a highly potent and differentiated small molecule TKI that binds inside the ATP pocket, and is active against both wild-type and resistant mutations, including solvent front and gatekeeper mutations. Repotrectinib is expected to enter the U.S. market in mid-December 2023.

Related Products